This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: A smart choice for patients when there’s no time to wait

Zinforo Mode of Action

Watch the video to explore the Zinforo mode of action1

A fifth-generation cephalosporin with coverage against key causative pathogens in children with cSSTI, including MRSA, and CAP, including penicillin susceptible strains of S. pneumoniae1,2

Zinforo has relatively low protein binding (<20%), and using data comparing protein binding with rate of penetration to the site of infection, is predicted to have a rapid penetration rate3,4

A safety and tolerability profile consistent with comparator therapies in clinical studies‡§5-8 and a similar safety profile in the paediatric population to that observed in adults.II​​​​​​​

Approved to treat neonates and infants <2 months of age with a proven clinical response in paediatric patients with cSSTI and CAP.9,10​​​​​​​

Explore more

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1-3,11

Learn more

‡ Zinforo is contraindicated in patients with hypersensitivity to any active substance or excipient and should not be used in patients with a history of hypersensitivity to other cephalosporin-class antibiotics or who have had an immediate and severe hypersensitivity reaction (e.g., anaphylaxis to other ß-lactam antibacterial agents). Fatal hypersensitivity reactions are possible. Antibacterial-associated colitis and pseudomembranous colitis (Clostridium difficile) have been reported, including cases that were life-threatening. Patients with a pre-existing seizure disorder should use Zinforo with caution as seizures occurred in toxicology studies at doses higher than typical human exposures. DAGT (Coombs test) became positive in 11.2% of patients from five pooled pivotal studies in patients who received Zinforo every 12 hours and in 32.3% of patients who received Zinforo every 8 hours.1
​​​​§Comparator therapies: cSSTI, ceftriaxone; CAP, vancomycin or cefazolin, plus optional aztreonam.
IIBased on two clinical trials in 227 paediatric patients aged from 2 months to 17 years. The most common adverse reactions occurring in ≥3% of patients treated with Zinforo were diarrhoea, rash and vomiting, and were generally mild or moderate in severity.9,10
Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1


CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

  1. ZINFORO. Summary of Product Characteristics
  2. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  3. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7
  4. Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57
  5. Corey G, et al. Clin Infect Dis 2010;51:641–50
  6. Santos PD, et al. J Chemother 2013;25:341–6
  7. Corrado ML. J Antimicrob Chemother 2010;65(Suppl 4):iv67–iv71
  8. Lodise TP, Low DE. Drugs 2012;72:1473–93 
  9. Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47
  10. Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–59
  11. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0219. September 2021


Explore the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI


Discover specific information on the use of Zinforo in neonates, infants and children here:

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?